Sandra Rajme-López, Bernardo A Martinez-Guerra, Carla M Román-Montes, Karla M Tamez-Torres, Andrea C Tello-Mercado, Karen M Tepo-Ponce, Zurisadai Segura-Ortíz, Abigail López-Aguirre, Orianlid Del Rocío Gutiérrez-Mazariegos, Oswaldo Lazcano-Delgadillo, Rafael Nares-López, María F González-Lara, David Kershenobich-Stalnikowitz, José Sifuentes-Osornio, Alfredo Ponce-de-León, Guillermo M Ruíz-Palacios
BACKGROUND: Even though worldwide death rates from coronavirus disease 2019 (COVID-19) have decreased, the threat of disease progression and death for high-risk groups continues. Few direct comparisons between the available severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals have been made. OBJECTIVE: We aimed to compare two SARS-CoV-2 antivirals (nirmatrelvir/ritonavir and remdesivir) against all-cause hospitalization or death. DESIGN: This is a propensity score-matched cohort study...
2024: Therapeutic Advances in Infectious Disease